Nanobiotix (NASDAQ:NBTX) Downgraded to Sell at Zacks Investment Research

Zacks Investment Research downgraded shares of Nanobiotix (NASDAQ:NBTX) from a hold rating to a sell rating in a research note published on Wednesday, Zacks.com reports.

According to Zacks, “Nanobiotix S.A. is a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer. The company’s proprietary technology includes NBTXR3. Nanobiotix S.A. is headquartered in Paris, France. “

NBTX opened at $11.83 on Wednesday. The business has a 50 day moving average price of $13.16 and a two-hundred day moving average price of $14.69. The company has a market cap of $412.11 million and a PE ratio of -7.40. Nanobiotix has a 52 week low of $11.53 and a 52 week high of $21.55.

An institutional investor recently raised its position in Nanobiotix stock. UBS Group AG grew its holdings in shares of Nanobiotix S.A. (NASDAQ:NBTX) by 20,183.8% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 70,182 shares of the company’s stock after purchasing an additional 69,836 shares during the period. UBS Group AG owned approximately 0.21% of Nanobiotix worth $1,055,000 at the end of the most recent reporting period. 13.93% of the stock is owned by institutional investors and hedge funds.

About Nanobiotix

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. The company develops NanoXray products to help patients receiving radiotherapy by enhancing the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues.

Featured Story: The benefits and drawbacks of dollar cost averaging

Get a free copy of the Zacks research report on Nanobiotix (NBTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.